Tag Archives: AB101

Rezolute Ultra-long-acting Basal Insulin (AB101) Ph1 Topline Results

Rezolute, Inc. (formerly AntriaBio) announced topline results for the Ph1 study evaluating its ultra-long acting basal insulin (AB101). Of note, Rezolute stated that based on results from the Ph1 study, additional formulation work must be performed before advancing the program. Below, FENIX provides brief insights into AB101 and its commercial potential.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.